News

e-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present ...
The Manila Times56m
e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP‑1/GIP receptor agonist or an FGF‑21 analogue. All mice receiving combination therapy ...